Oxidation of amine-based pharmaceuticals with unactivated peroxymonosulfate: Kinetics, mechanisms, and elimination efficiency of NDMA formation.

Amine-based pharmaceuticals are a significant class of N-nitrosodimethylamine (NDMA) precursors. This study investigated the use of unactivated peroxymonosulfate (PMS) to control amine-based pharmaceuticals and their NDMA formation potential. Kinetic analysis and product identification revealed that sumatriptan and doxylamine primarily underwent reactions at their tertiary amine group, while ranitidine and nizatidine had both tertiary amine and thioether group as reaction sites. The NDMA formation from sumatriptan and doxylamine during post-chloramination was significantly reduced with the abatement of the parent contaminants, while the formation of NDMA remained high even if full abatement of ranitidine and nizatidine was achieved. Product formation kinetics and reference standard tests revealed the great contribution of transformation products to NDMA formation. Ranitidine could be oxidized to sulfoxide-type product ranitidine-SO and N-oxide type product ranitidine-NO. Ranitidine-SO exhibited a high NDMA yield comparable to that of ranitidine (>90%), while ranitidine-NO showed a low NDMA yield (2%). With further oxidation of ranitidine-SO at the tertiary amine group, NDMA formation was reduced by more than 90%. The underlying mechanism for the importance of the tertiary amine group in NDMA formation was demonstrated by quantum chemical calculation. These findings underscore the potential of PMS pre-oxidation on NDMA control.

Segmental Hair Analysis-Interpretation of the Time of Drug Intake in Two Patients Undergoing Drug Treatment.

The present study involved segmental testing of hair in two clinical cases with known dosage histories. Hair analysis confirmed the first patient's exposure to the prescribed sertraline and citalopram for several months. Citalopram was generally distributed along the hair shaft in accordance with the drug ingestion period. By contrast, "false" positive results were observed for sertraline in distal hair segments, corresponding to a period of no sertraline exposure, which may indicate incorporation from sweat or sebum, which transport the drugs along the hair surface. The second patient received various drugs during her treatment for brain cancer. Metoclopramide, morphine, oxazepam, paracetamol, sumatriptan, tramadol, and zopiclone, which had been part of the therapy, were all detected in the proximal hair segment. The results of these two cases indicated that results-especially concerning the time of drug intake-must be interpreted with caution and allow for the possibility of incorporation from sweat or sebum.

Identification and characterization of stress degradation products of sumatriptan succinate by using LC/Q-TOF-ESI-MS/MS and NMR: Toxicity evaluation of degradation products.

Sumatriptan succinate, a selective 5-HT1B receptor agonist, was subjected to forced degradation studies as per to International Conference on Harmonization-specified conditions. The drug exclusively showed its degradation under basic, photolytic, and oxidative stress conditions, whereas it was found to be stable under acidic, thermal, and neutral conditions. Eight (DP-1 to DP-8) degradation products were identified and characterized by UPLC-ESI/MS/MS experiments combined with accurate mass measurements. The effective chromatographic separation was achieved on Hibar Purospher STAR, C18 (250 × 4.6 mm, 5 µm) column using mobile phase consisting of 0.1% formic acid and methanol at a flow rate of 0.6 mL/minute in gradient elution method. It is noteworthy that 2 major degradation products DP-3 and DP-7 were isolated using preparative HPLC and characterized by advanced NMR experiments. The degradation pathway of the sumatriptan was established, which was duly justified by mechanistic explanation. In vitro cytotoxicity of isolated DPs was tested on normal human cells such as HEK 293 (embryonic kidney cells) and RWPE-1 (normal prostate epithelial cells). This study revealed that they were nontoxic up to 100 µm concentration. Further, in silico toxicity of the drug and its degradation products was determined using ProTox-II prediction tool. This study revealed that DP-4 and DP-8 are predicted for immune toxicity. Amine oxidase A and prostaglandin G/H synthase 1 are predicted as toxicity targets for DP-3, DP-4, and DP-6 whereas DP-1 and DP-2 are predicted for amine oxidase A target.

Quality-by-design-based ultra high performance liquid chromatography related substances method development by establishing the proficient design space for sumatriptan and naproxen combination.

Quality-by-design-based methods hold greater level of confidence for variations and greater success in method transfer. A quality-by-design-based ultra high performance liquid chromatography method was developed for the simultaneous assay of sumatriptan and naproxen along with their related substances. The first screening was performed by fractional factorial design comprising 44 experiments for reversed-phase stationary phases, pH, and organic modifiers. The results of screening design experiments suggested phenyl hexyl column and acetonitrile were the best combination. The method was further optimized for flow rate, temperature, and gradient time by experimental design of 20 experiments and the knowledge space was generated for effect of variable on response (number of peaks ≥ 1.50 - resolution). Proficient design space was generated from knowledge space by applying Monte Carlo simulation to successfully integrate quantitative robustness metrics during optimization stage itself. The final method provided the robust performance which was verified and validated. Final conditions comprised Waters® Acquity phenyl hexyl column with gradient elution using ammonium acetate (pH 4.12, 0.02 M) buffer and acetonitrile at 0.355 mL/min flow rate and 30°C. The developed method separates all 13 analytes within a 15 min run time with fewer experiments compared to the traditional quality-by-testing approach.

Development and validation of a high performance chromatographic method for determining sumatriptan in niosomes.

In this paper, a novel, precise, specific, accurate and rapid reversed-phase high performance liquid chromatographic method was developed, optimized and validated for determining sumatriptan succinate in niosomes with the best chromatographic peak resolution, reduced run time and low cost of analysis. The formulation has been previously optimized in terms of composition and preparation technique to obtain a high drug encapsulation efficiency and adequate vesicle size distribution. This method showed the best resolution by using Spherisorb OSD2 C18 column (250 mm × 4.6 mm, 5 µm) using phosphate buffer (0.05 M):acetonitrile (80:20, v/v; pH adjusted to 6.0) as a mobile phase at a flow rate of 1 mL/min and wavelength of 214 nm. The main objective of this research was to demonstrate the robustness of the reversed-phase HPLC method development by applying the Taguchi robust methodology. The signal-to-noise ratio (S/N) was employed as a quality measurement. This tool permits to establish the influence of some selected factors (acetonitrile:phosphate ratio, pH buffer, oven temperature and flow rate) on two responses (peak areas and retention time). On the basis of the results obtained, we can conclude that this analytical method was robust for all the factors studies, as exception of the flow rate, where the higher quality was obtained for the fewer values (0.8 mL/min). Therefore, this parameter must be carefully controlled when this method was employed, to avoid any modification in the peak areas overall.

Stability-indicating micellar electrokinetic chromatography method for the analysis of sumatriptan succinate in pharmaceutical formulations.

A micellar electrokinetic chromatography method for the determination of sumatriptan succinate in pharmaceutical formulations was developed. The effects of several factors such as pH, surfactant and buffer concentration, applied voltage, capillary temperature, and injection time were investigated. Separation took about 5 min using phenobarbital as internal standard. The separation was carried out in reversed polarity mode at 20 °C, 26 kV and using hydrodynamic injection for 10s. Separation was achieved using a bare fused-silica capillary 50 µm×40 cm and background electrolyte of 25 mM sodium dihydrogen phosphate-adjusted with concentrated phosphoric acid to pH 2.2, containing 125 mM sodium dodecyl sulfate and detection was at 226 nm. The method was validated with respect to linearity, limits of detection and quantification, accuracy, precision and selectivity. The calibration curve was linear over the range of 100-2000 µg mL(-1). The relative standard deviations of intra-day and inter-day precision for migration time, peak area, corrected peak area, ratio of corrected peak area and ratio of peak area were less than 0.68, 3.48, 3.28, 2.97 and 2.83% and 2.01, 5.50, 4.46, 4.92 and 4.07%, respectively. The proposed method was successfully applied to the determinations of the analyte in tablet. Forced degradation studies were conducted by introducing a sample of sumatriptan succinate standard solution to different forced degradation conditions using neutral (water), basic (0.1 M NaOH), acidic (0.1 M HCl), oxidative (10% H(2)O(2)) and photolytic (exposure to UV light at 254 nm for 2 h). It is concluded that the stability-indicating method for sumatriptan succinate can be used for the analysis of the drug in various samples.

Electrocatalytic determination of sumatriptan on the surface of carbon-paste electrode modified with a composite of cobalt/Schiff-base complex and carbon nanotube.

The electrochemical oxidation of sumatriptan on the surface of carbon paste electrode modified with multi-walled carbon nanotube and cobalt methyl-salophen complex is studied by using cyclic voltammetry and polarization studies. The results indicate that the drug is irreversibly oxidized in a one electron oxidation mechanism. It was found that the peak potential shifted negatively with increasing pH, confirms that H(+) participate in the oxidation process. The electrode is shown to be very effective for the detection of sumatriptan in the presence of other biological reductant compounds. The prepared modified electrode exhibits a very good resolution between the voltammetric peaks of sumatriptan, ascorbic acid and uric acid, which makes it suitable for the simultaneous detection of sumatriptan in the presence of these compounds in clinical and pharmaceutical preparations. It can be concluded that multi-walled carbon nanotube and Shiff base complex have synergic effect on electroacatalytic oxidation of sumatriptan. A linear range of 1-1000µM and detection limit of 0.3µM was obtained for sumatriptan from DPV measurements using this electrode in 0.1M acetate buffered solution of pH 5.0. The electrode has been applied successfully for the determination of sumatriptan in synthetic serum and commercial tablets.

Development and validation of a sensitive and rapid method to determine naratriptan in human plasma by LC-ESI-MS-MS: application to a bioequivalence study.

A simple, sensitive, selective, and rapid high-performance liquid chromatography-tandem mass spectrometry method is developed and validated for the quantitation of naratriptan, using sumatriptan as internal standard (IS). The method included liquid-liquid extraction of naratriptan and IS with methyl-tert-butyl ether and dichloromethane mixture from 100 µL human plasma. The chromatographic separation is achieved on ACE C18 (50 mm × 2.1 mm, 5 µm) analytical column under isocratic conditions, using 0.1% acetic acid and acetonitrile (15:85, v/v) at a flow-rate of 0.4 mL/min. The precursor → product ion transitions for naratriptan (m/z 336.10 → 98.06) and IS (m/z 296.09 → 251.06) were monitored on a triple quadrupole mass spectrometer, operating in the multiple reaction monitoring (MRM) and positive ion mode. The linearity of the method for naratriptan is determined in the range of 103-20690 pg/mL with the analysis time of 1.5 min. The method is fully validated according to USFDA guidelines. A systematic post-column infusion study is conducted for ion-suppression due to endogenous matrix components. The process efficiency of analyte (96%) and IS (93%) from spiked plasma samples was consistent and reproducible. The application of the method is demonstrated by a bioequivalence study of 2.5 mg naratriptan tablet formulation in 31 healthy volunteers under fasting conditions.

Voltammetric studies of sumatriptan on the surface of pyrolytic graphite electrode modified with multi-walled carbon nanotubes decorated with silver nanoparticles.

Multi-walled carbon nanotube decorated with silver nanoparticles (AgNPs-MWCNT) is used as an effective strategy for modification of the surface of pyrolytic graphite electrode (PGE). This modification procedure improved colloidal dispersion of the decorated MWCNTs in water, affording uniform and stable thin films for altering the surface properties of the working electrode. Robust electrode for sensing applications is obtained in a simple solvent evaporation process. The electrochemical behavior of sumatriptan (Sum) at the bare PGE and AgNPs-MWCNT modified PGE is investigated. The results indicate that the AgNPs-MWCNT modified PGE significantly enhanced the oxidation peak current of Sum. A remarkable enhancement in microscopic area of the electrode together with strong adsorption of Sum on the surface of the modified electrode resulted in a considerable increase in the peak current of Sum. Experimental parameters, such as scan rate, pH, accumulation conditions and amount of the modifier used on the PGE surface are optimized by monitoring the CV responses toward Sum. It is found that a maximum current response can be obtained at pH 7.4 after accumulation at open circuit for 150 s. Further experiments demonstrated that the oxidative peak currents increased linearly with Sum concentration in the range of 8.0 x 10(-8)-1.0 x 10(-4)mol L(-1) with a detection limit of 4.0 x 10(-8) mol L(-1). The modified electrode showed high sensitivity, selectivity, long-term stability and remarkable voltammetric reproducibility in response to Sum. These excellent properties make the prepared sensor suitable for the analysis in pharmaceutical and clinical preparations. The modified electrode was successfully applied for the accurate determination of trace amounts of Sum in pharmaceutical preparations.

Método HPLC para la determinación del sumatriptán en plasma y tejido cerebral / HPLC method for the determination of sumatriptan in plasma and brain tissue

Se ha desarrollado un método de cromatografía de líquidos de alto rendimiento ultravioleta sensible y rápido y se ha validado para la determinación del sumatriptán, un agonista de serotonina, en muestras de homogeneizado de cerebro y plasma de rata. Una vez realizada una extracción líquido-líquido de sumatriptán y ofl oxacina (estándar interno), los compuestos se separaron en una columna de fase inversa C-18, eluida con un 22% de acetonitrilo y un 78% de tampón fosfato amónico (0,04 M, PH ajustado 3,7) y detectada a 228 nm. Este método muestra una buena linealidad para las muestras de plasma y tejido cerebral con un rango de concentración muy amplio de 3–2000 ng/ml y 3-1000 ng/g respectivamente, y un coefi ciente de correlación de 0,9998 y 0,9994. Con este método se obtuvieron buenos resultados de precisión (CV interdía e intradía < 9,1%) y exactitud (margen de error interdía e intradía < 7,3%). El límite de la concentración de cuantifi cación fue 3 de ng/ml. La recuperación absoluta del sumatriptán fue superior al 93,4% para el plasma y al 89,5% para las muestras de tejido cerebral. Este método es sencillo, rápido y sensible. El método propuesto podría resultar ventajoso en la estimación del sumatriptán incorporado en sistemas de administración que concentran el fármaco en plasma y en muestras de tejido cerebral y se podría utilizar en estudios farmacocinéticos en modelos animales

A rapid and sensitive ultra-violet high-performance liquid chromatographic method was developed and validated for the determination of sumatriptan, a serotonin agonist in rat plasma and brain homogenate samples. After a liquid–liquid extraction of sumatriptan and ofl oxacin (internal standard) , the compounds were separated on a reversed-phase C-18 column, eluted with 22% of acetonitrile and 78% of ammonium phosphate buffer (0.04 M, adjusted pH 3.7) and detected at 228 nm. This method shows a good linearity for plasma and brain samples with very wide concentration range of 3–2000 ng/ml and 3-1000 ng/g respectively, and correlation coeffi cient of 0.9998 and 0.9994. A good precision (inter and intra day CV < 9.1%) and a good accuracy (inter and intra day bias < 7.3%) was obtained with this method. The limit of quantifi cation concentration was 3 ng/ml. The absolute recovery of sumatriptan was higher than 93.4% for plasma and 89.5% for brain samples. This method is simple, rapid and sensitive. The proposed method could be advantageous in estimation of sumatriptan incorporated into delivery systems that concentrate drug in plasma as well as brain tissues and could be used for pharmacokinetics studies in animal model

High-performance liquid chromatographic determination of sumatriptan after in vitro transdermal diffusion studies.

A simple, accurate, precise and rapid HPLC method with UV detection has been validated in order to determine the in vitro transdermal absorption of sumatriptan succinate. The HPLC method is a modification of that described by Nozal et al. [M.J. Nozal, J.L. Bernal, L. Toribio, M.T. Martin, F.J. Diez, J. Pharm. Biomed. Anal. 30 (2002) 285-291]. Separation was carried out on a 250 mm Kromasil C18 column at room temperature. The detector response, at 282.7 nm, was found to be linear in a concentration range between 0.145 and 145 microM. The limit of detection (LOD) was 0.019 microM and the limit of quantification (LOQ) was 0.145 microM.

Stability-indicating methods for the determination of sumatriptan succinate.

Four stability-indicating methods were developed for the determination of sumatriptan succinate in the presence of its degradation products. The first method depends on the quantitative densitometric evaluation of thin-layer chromatography of sumatriptan succinate in the presence of its degradation products without any interference. Cyclohexane-dichloromethane-diethylamine (50:40:10 v/v/v) was used as a mobile phase and the chromatogram was scanned at 228 nm. This method determines sumatriptan succinate in the concentration range l-8 microg per spot with mean percentage recovery 100.52+/-1.23%. The second and third methods depend on the use of first-derivative (D(1)) and second-derivative (D(2)) spectrophotometry at 234 and 238 nm, respectively. These methods determine the drug in the concentration range 1.25-10 microg x ml(-1) with mean percentage recovery 99.91+/-1.01% and 99.96+/-1.13% for (D(1)) and (D(2)), respectively. The fourth method depends on the use of ratio derivative spectrophotometric technique. The amplitude in the first derivative of the ratio spectra at 235 nm was selected to determine the cited drug in the presence of its degradation products. Calibration graph is linear in the concentration range 1.25-10 microg x ml(-1) with mean percentage recovery 100.19+/-1.19%. The suggested methods were successfully applied for determining sumatriptan succinate in bulk powder, laboratory-prepared mixtures and pharmaceutical dosage forms (Imigran tablet) with good accuracy and precision. The results obtained by applying the proposed methods were statistically analyzed and compared with those obtained by the reported method.

Development and validation of an LC assay for sumatriptan succinate residues on surfaces in the manufacture of pharmaceuticals.

A high performance liquid chromatographic (HPLC) method for the assay of sumatriptan succinate residues in swabs collected from manufacturing equipment surfaces was developed and validated in order to control a cleaning procedure. The swabbing procedure using two cotton swabs moistened with water was validated applying a wipe-test and a HPLC method developed to determine low quantities of the drug. The HPLC method involves a C18 column at 25 degrees C, a mixture of ammonium phosphate monobasic (0.05 M)-acetonitrile (84:16, v/v) as a mobile phase and UV detection at 228 nm. Using the proposed method, the average recoveries obtained are of 88.5% for vinyl, 94.2% for glass and 95.2% for stainless steel plates with RSD of 5.5 (n=36), 2.3 (n=36), 2.2% (n=36), respectively. The method was successfully applied to the assay of real swab samples collected from the equipment surfaces.

Determination of degradation products of sumatriptan succinate using LC-MS and LC-MS-MS.

Acid, base, heat, oxidation and UV irradiation stress methods were applied to study the stability of the bulk drug form of sumatriptan succinate. Liquid chromatography coupled with mass spectrometry (LC-MS and LC-MS-MS) was used to analyze the degraded samples and tentative structural identifications were assigned based upon known reactivity of the drug, molecular weight measurements and MS-MS fragmentation patterns. Sumatriptan succinate was found to be stable to exposure of acid, base, oxidation and UV irradiation at ambient conditions, but was found to degrade under acidic, basic and oxidative conditions when heated to 90 degrees C.

Determination of naloxone in human plasma by high-performance liquid chromatography with coulometric detection.

Naloxone, the analyte and the internal standard, sumatriptan, are extracted from plasma using solid-phase extraction columns. Chromatography and detection are performed using isocratic reversed-phase high-performance liquid chromatography (HPLC) with coulometric end-point detection. The standard curve was linear over the range 0-50 ng/ml of naloxone in plasma. The reproducibility, the coefficient of variation (C.V.) of the method over the range of the standard curve was 6.2-11.2%. The recovery averaged 90.4 +/- 8.9%. A plasma profile following i.v. administration of naloxone in one normal healthy volunteer is presented.

Screening and identification of sumatriptan and its main metabolite by means of thin-layer chromatography, ultraviolet spectroscopy and gas chromatography/mass spectrometry.

Sumatriptan (CAS 103628-46-2, 3-[2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide++ +), a substance for treatment of acute migraine attacks, and its main metabolite are investigated by thinlayer chromatography (TLC), ultraviolet spectroscopy, and gas chromatography/mass spectrometry (GC/MS). The resulting analytical data (correlated hRf-values, UV solvent spectra, remission spectra, GC retention indices, and electron impact (EI) mass spectra) including an extraction procedure and different derivatization methods are presented. Their applicability is described for urine analysis.